Profile data is unavailable for this security.
About the company
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus primarily on MC1r agonists, with the potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. Its product candidates include PL9643 for dry eye disease and PL8177 for the treatment of ulcerative colitis.
- Revenue in USD (TTM)5.90m
- Net income in USD-32.20m
- Incorporated1986
- Employees34.00
- LocationPalatin Technologies Inc4B Cedar Brook DriveCRANBURY 08512United StatesUSA
- Phone+1 (609) 495-2200
- Fax+1 (609) 495-2202
- Websitehttps://www.palatin.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NanoViricides Inc | 0.00 | -9.51m | 19.61m | 7.00 | -- | 1.84 | -- | -- | -0.8115 | -0.8115 | 0.00 | 0.9017 | 0.00 | -- | -- | 0.00 | -63.30 | -43.54 | -65.85 | -46.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.94 | -- | -8.90 | -- |
| Nymox Pharmaceutical Corp | 0.00 | -8.84m | 19.64m | 3.00 | -- | -- | -- | -- | -0.0966 | -0.0966 | 0.00 | -0.0339 | 0.00 | -- | -- | -- | -785.44 | -306.39 | -- | -749.37 | -- | -- | -- | -43,683.47 | -- | -157.57 | -- | -- | -- | -- | -34.49 | -- | -39.16 | -- |
| Goldenwell Biotech Inc | 940.00 | -137.11k | 19.80m | -- | -- | 5,169.71 | -- | 21,063.83 | -0.0014 | -0.0014 | 0.00001 | 0.00004 | 0.0048 | 0.0031 | -- | -- | -69.82 | -- | -70.29 | -- | 42.55 | -- | -14,586.17 | -- | 21.43 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
| Minerva Neurosciences Inc | 0.00 | -33.65m | 19.93m | 9.00 | -- | -- | -- | -- | -4.44 | -4.44 | 0.00 | -6.36 | 0.00 | -- | -- | 0.00 | -59.32 | -49.89 | -62.70 | -52.39 | -- | -- | -- | -442.65 | -- | -- | -- | -- | -- | -- | 6.55 | -- | -- | -- |
| MEI Pharma Inc | 66.75m | 26.16m | 20.26m | 46.00 | 0.7744 | 0.3969 | 0.764 | 0.3034 | 3.93 | 3.93 | 10.02 | 7.66 | 0.6498 | -- | 29.15 | 1,451,174.00 | 25.46 | -25.31 | 30.38 | -28.59 | -- | -- | 39.18 | -122.05 | -- | -- | 0.00 | -- | 19.95 | 97.56 | 41.53 | -- | -- | -- |
| Vincerx Pharma Inc | 0.00 | -28.90m | 20.41m | 42.00 | -- | 1.32 | -- | -- | -1.31 | -1.31 | 0.00 | 0.5206 | 0.00 | -- | -- | 0.00 | -101.76 | -- | -136.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 36.24 | -- | -- | -- |
| Pieris Pharmaceuticals Inc | 20.87m | -23.82m | 21.34m | 46.00 | -- | 1.14 | -- | 1.02 | -19.12 | -19.12 | 16.67 | 14.17 | 0.3707 | -- | 17.13 | 453,739.10 | -42.31 | -28.41 | -66.27 | -39.69 | -- | -- | -114.11 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| Palatin Technologies, Inc. | 5.90m | -32.20m | 21.95m | 34.00 | -- | 13.90 | -- | 3.72 | -2.39 | -2.39 | 0.4275 | 0.0979 | 0.3189 | 0.6402 | 6.95 | 173,588.80 | -173.98 | -26.11 | -387.23 | -30.68 | 96.58 | -- | -545.58 | -126.20 | 1.20 | -- | 0.0443 | -- | 230.53 | -40.87 | 23.91 | -- | 80.82 | -- |
| Geovax Labs Inc | 300.68k | -26.92m | 22.56m | 17.00 | -- | -- | -- | 75.03 | -13.05 | -13.05 | 0.1389 | -0.5526 | 0.0237 | -- | -- | 17,687.06 | -212.40 | -108.34 | -362.39 | -147.24 | -- | -- | -8,951.51 | -1,842.93 | -- | -- | -- | -- | -100.00 | -- | -85.20 | -- | -- | -- |
| Hcw Biologics Inc | 3.92m | -38.37m | 22.69m | 45.00 | -- | -- | -- | 5.78 | -1.04 | -1.04 | 0.1068 | -0.1666 | 0.1183 | -- | 5.76 | 87,170.22 | -115.73 | -- | -199.07 | -- | 31.17 | -- | -978.10 | -- | -- | -146.50 | 2.75 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| SAB Biotherapeutics Inc | 2.78m | -40.32m | 23.63m | 57.00 | -- | 0.5123 | -- | 8.50 | -5.69 | -5.69 | 0.3646 | 5.00 | 0.0571 | -- | 9.44 | 48,773.51 | -82.85 | -- | -102.37 | -- | -- | -- | -1,450.32 | -- | -- | -- | 0.0817 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| Biora Therapeutics Inc | 860.00k | -86.81m | 23.74m | 58.00 | -- | -- | -- | 27.60 | -5.57 | -5.56 | 0.024 | -2.49 | 0.0253 | -- | 1.05 | 14,827.59 | -255.56 | -122.84 | -- | -369.01 | -- | -- | -10,094.19 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
| RenovoRx Inc | 0.00 | -8.11m | 23.75m | 8.00 | -- | 2.56 | -- | -- | -0.6059 | -0.6059 | 0.00 | 0.3868 | 0.00 | -- | -- | 0.00 | -88.58 | -- | -106.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
| Bolt Biotherapeutics Inc | 11.17m | -66.17m | 23.79m | 100.00 | -- | 0.2771 | -- | 2.13 | -1.74 | -1.74 | 0.2938 | 2.24 | 0.0709 | -- | -- | 111,660.00 | -42.03 | -48.32 | -47.37 | -54.03 | -- | -- | -592.57 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| Unity Biotechnology Inc | 0.00 | -27.86m | 23.92m | 19.00 | -- | 1.21 | -- | -- | -1.80 | -1.80 | 0.00 | 1.17 | 0.00 | -- | -- | 0.00 | -36.05 | -47.21 | -45.11 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| Cognition Therapeutics Inc | 0.00 | -31.08m | 24.04m | 25.00 | -- | 1.04 | -- | -- | -0.9317 | -0.9317 | 0.00 | 0.5736 | 0.00 | -- | -- | 0.00 | -79.36 | -- | -104.49 | -- | -- | -- | -- | -- | -- | -263.29 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Palatin Technologies Inc's reporting currency: US Dollar USD
14.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Jun 2024 | 1.68m | 8.66% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 590.84k | 3.05% |
| LPL Financial LLCas of 30 Jun 2024 | 186.40k | 0.96% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 141.83k | 0.73% |
| Geode Capital Management LLCas of 30 Jun 2024 | 134.66k | 0.70% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 45.20k | 0.23% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 31.60k | 0.16% |
| Montis Financial LLCas of 30 Jun 2024 | 20.96k | 0.11% |
| XTX Markets LLCas of 30 Jun 2024 | 14.63k | 0.08% |
| Kestra Advisory Services LLCas of 30 Jun 2024 | 12.87k | 0.07% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
